<DOC>
	<DOCNO>NCT00226915</DOCNO>
	<brief_summary>The purpose study compare progression-free survival conventional paclitaxel carboplatin vs weekly paclitaxel carboplatin patient newly diagnose stage II-IV ovarian epithelial , primary peritoneal , fallopian tube cancer .</brief_summary>
	<brief_title>Trial Tri-weekly TJ Versus Weekly TJ Stage II-IV Mullerian Carcinoma</brief_title>
	<detailed_description>This randomize , multicenter study . Patients stratify accord residual disease 1 cm less vs 1cm , stage II v III v IV , histology ( clear cell mucinous vs. serous others ) . Patients randomize one two treatment arm . Arm I : Patients receive paclitaxel IV 3 hour carboplatin IV 60 minute day 1 6-9 cycle . Arm II : Patients receive paclitaxel IV 1 hour day 1 , 8 , 15 carboplatin IV 60 minute day 1 6-9 cycle . In arm , cycle repeat 6 cycle every 21 day absence disease progression unacceptable toxicity . Additional 3 cycle give clinical partial complete response 6 cycle . PROJECTED ACCRUAL : A total 600 patient ( 300 per treatment arm ) accrue study within 3 year . Assuming median progression-free survival 16 month 21 month recruitment period 3 year achieve recruit 600 patient design 80 % detect difference two arm two-sided 5 % level statistical significance .</detailed_description>
	<mesh_term>Fallopian Tube Neoplasms</mesh_term>
	<mesh_term>Neoplasms , Glandular Epithelial</mesh_term>
	<mesh_term>Ovarian Neoplasms</mesh_term>
	<mesh_term>Paclitaxel</mesh_term>
	<mesh_term>Albumin-Bound Paclitaxel</mesh_term>
	<mesh_term>Carboplatin</mesh_term>
	<criteria>Histologically confirm stage IIIV ovarian epithelial , primary peritoneal , fallopian tube cancer No prior chemotherapy Age : 20 Performance status : ECOG 03 1 ) Absolute neutrophil count least 1,500/mm3 2 ) Platelet count least 100,000/mm3 3 ) Bilirubin le 1.5mg/dL 4 ) SGOT le 100 IU/l 5 ) Serum creatinine le 1.5mg/dL Written informed consent Patients ovarian borderline tumor Patients evidence cancer present within last 5 year exception carcinoma situ intramucosal cancer curable local therapy Patients active infection uncontrolled diabetes Patients unstable angina , myocardial infarction within past 6 month , patient serious arrythmia require medication Patients history hypersensitivity polyoxyethylated castor oil ( Cremophor EL )</criteria>
	<gender>Female</gender>
	<minimum_age>20 Years</minimum_age>
	<maximum_age>N/A</maximum_age>
	<verification_date>April 2012</verification_date>
	<keyword>ovarian neoplasm</keyword>
	<keyword>randomize control trial</keyword>
	<keyword>paclitaxel</keyword>
	<keyword>carboplatin</keyword>
</DOC>